Previous 10 | Next 10 |
Jazz Pharmaceuticals plc (JAZZ) Q4 2021 Earnings Conference Call March 1, 2022 4:30 PM ET Company Participants Andrea Flynn - VP & Head, IR Bruce Cozadd - Co-Founder, Chairman & CEO Daniel Swisher - President Robert Iannone - EVP, Research & Development & Chief Medical Officer...
Jazz Pharmaceuticals press release (NASDAQ:JAZZ): Q4 Non-GAAP EPS of $4.21 beats by $0.58. Revenue of $896.73M (+34.7% Y/Y) beats by $30.02M. Shares -1.05%. Growing and durable commercial franchises drove 2021 total revenues of $3.1 billion; 31% increase compared to 2020 Significant deleverag...
JAZZ PHARMACEUTICALS ANNOUNCES FULL YEAR AND FOURTH QUARTER 2021 FINANCIAL RESULTS PR Newswire DUBLIN , March 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2021 and provid...
Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences Cowen Health Care Conference Needham Virtual Neuroscience Forum PR Newswire DUBLIN , Feb. 28, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the ...
Jazz Pharmaceuticals to Report 2021 Fourth Quarter and Full Year Financial Results on March 1, 2022 PR Newswire DUBLIN , Feb. 15, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2021 fourth quarter and...
The second part to my series on the Biotechnology industry will be finding the necessary skills to research companies. The concepts are simple, but the information is sometimes difficult to find, and so I provide some examples. The five companies I analyze are just examples, and u...
Jazz Pharmaceuticals laid out its 2025 vision at the J.P. Morgan Healthcare Conference last month. The company expects to generate $5 billion in revenues in 2025 and a five percentage points operating margin improvement. The margin goal seems achievable but there are risks on the ...
Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net present value calculations, it is quite easy to find a basket that fulfills your p...
Jazz Pharmaceuticals faces increased competition after a competitor was able to manufacture a generic version of their Narcolepsy drug Xyrem. The market for Narcolepsy, which is Jazz Pharm’s best-performing drug market, has a stable yet extremely slow growth rate. The compa...
Jazz Pharmaceuticals (JAZZ -0.5%) completed the submission of a supplemental biologics license application to the U.S. Food and Drug Administration seeking approval for a Monday/Wednesday/Friday intramuscular dosing schedule for Rylaze for use as a component of a multi-agent chemotherape...
News, Short Squeeze, Breakout and More Instantly...
Jazz Pharmaceuticals plc Company Name:
JAZZ Stock Symbol:
NASDAQ Market:
Jazz Pharmaceuticals plc Website:
Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting PR Newswire Ms. Hamill brings extensive experience and proven leadership focused on commercial growth and shareholder value DUBLIN , July 25, 20...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / Jazz Pharmaceuticals Originally published by Jazz Pharmaceuticals In celebration of Pride Month , we were joined by Celia Sandhya Daniels (she/they) who led an insightful discussion aimed at educating, raising awareness and calling for unders...
Jazz Pharmaceuticals Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes due 2026 PR Newswire DUBLIN , July 22, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ...